This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix resubmits new drug application for Dextenza

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix has resubmitted a new drug application to the FDA for its ocular pain treatment Dextenza, the company announced in a press release.

Dextenza (dexamethasone insert 0.4 mg) is a corticosteroid intracanalicular insert placed through the punctum to deliver dexamethasone for up to 30 days.

A complete response letter from the FDA in July 2017 cited manufacturing deficiencies, the release said. This resubmission addresses those citations.

“Since last July, we have worked to make substantial improvements in our manufacturing processes and quality oversight that have allowed us to reach this important milestone,” Antony Mattessich, president and CEO of Ocular Therapeutix, said in the release. “However, while the resubmission is significant, our focus remains on the end goal of making Dextenza available to physicians and patients.”

The company expects a 6-month review with a possible target action date under the Prescription Drug User Fee Act at the end of 2018, the release said.